BCL2 and B-cell chronic lymphocytic leukemia: Here, we assessed the combination of APG-115 with BCL-2 inhibitor ABT-199 (also known as venetoclax), one of the most active chemotherapeutic agents in the therapy of CLL (Roberts et al., 2016).